NCT03906253

Brief Summary

This study is following up on previous studies that have demonstrated that geriatric subjects respond different to ultraviolet B (UVB) light than young subjects. The treatment of geriatric skin with dermal rejuvenation therapies (dermabrasion, fractionated laser resurfacing) restores the appropriate UVB response. Ongoing studies have tested the ability of fractionated laser resurfacing (FLR) to assess how long this wounding effect lasts-and have found that this appears to be a durable response which lasts for at least two years. The findings that FLR protects geriatric skin at two years is the impetus for this study. This study is an interventional study to assess if FLR treatment of one forearm of geriatric subjects with multiple actinic keratosis will result in the short-term removal of actinic keratosis, and the long-term decrease in levels of future actinic keratosis and other non-melanoma skin cancers in comparison to the untreated arm. Study length and visit: The first part of the study is completed in 1 day then there are follow up visits at 90 days and every 6 months for 5 years.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
72

participants targeted

Target at P50-P75 for not_applicable

Timeline
32mo left

Started Jan 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Jan 2018Dec 2028

Study Start

First participant enrolled

January 10, 2018

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

April 4, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 8, 2019

Completed
9.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

March 25, 2025

Status Verified

March 1, 2025

Enrollment Period

10.9 years

First QC Date

April 4, 2019

Last Update Submit

March 24, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change From Baseline in the Number of Actinic Keratosis due to FLR treatment.

    Investigator will assess the number of actinic keratosis on both forearms.

    up to 5 years

  • Change From Baseline in the Number Non-Melanoma Skin Cancers due to FLR treatment.

    Investigator will assess the number of actinic keratosis on both forearms.

    up to 5 years

Study Arms (2)

Factionated Laser Resurfacing - Right Arm

EXPERIMENTAL

Right forearm treatment of fractionated laser resurfacing.

Device: Fractionated Laser Resurfacing

Factionated Laser Resurfacing - Left Arm

EXPERIMENTAL

Left forearm treatment of fractionated laser resurfacing.

Device: Fractionated Laser Resurfacing

Interventions

A rejuvenating laser that makes tiny holes in the very superficial part of the skin.

Factionated Laser Resurfacing - Left ArmFactionated Laser Resurfacing - Right Arm

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with Actinic Keratosis within the past 6 months
  • At least 60 years of age, or older
  • Ability to comprehend procedures and risks versus benefits
  • Able to provide Informed Consent
  • Fair Skin (Fitzpatrick Type I or II)
  • Possess both Right and Left Forearms

You may not qualify if:

  • Uncontrolled Diabetes Mellitus
  • Not able to comprehend procedures or risks versus benefits
  • Pregnant or nursing
  • Large tattoos on forearms
  • History of abnormal healing or scarring (i.e., keloids)
  • Any disease that gets worse while in the sun
  • Use of topical or oral anti-inflammatory medication or steroids
  • Allergy to lidocaine
  • Current use of photosensitizing medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dayton VA Medical Center

Dayton, Ohio, 45428, United States

RECRUITING

Related Publications (2)

  • Spandau DF, Chen R, Wargo JJ, Rohan CA, Southern D, Zhang A, Loesch M, Weyerbacher J, Tholpady SS, Lewis DA, Kuhar M, Tsai KY, Castellanos AJ, Kemp MG, Markey M, Cates E, Williams AR, Knisely C, Bashir S, Gabbard R, Hoopes R, Travers JB. Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia. J Clin Invest. 2021 Oct 1;131(19):e150972. doi: 10.1172/JCI150972.

  • Chen R, Wargo JJ, Williams A, Cates E, Spandau DF, Knisely C, Travers JB. Single Ablative Fractional Resurfacing Laser Treatment For Forearm Actinic Keratoses: 6-Month Follow-Up Data From An Intrapatient Comparison Between Treated and Untreated Sites. Lasers Surg Med. 2020 Jan;52(1):84-87. doi: 10.1002/lsm.23175. Epub 2019 Nov 17.

MeSH Terms

Conditions

Keratosis, Actinic

Condition Hierarchy (Ancestors)

Precancerous ConditionsNeoplasmsKeratosisSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Jeffrey B Travers, MD, PhD

    Wright State University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Manager, Clinical Research Operations

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2019

First Posted

April 8, 2019

Study Start

January 10, 2018

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2028

Last Updated

March 25, 2025

Record last verified: 2025-03

Locations